UY27662A1 - MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY. - Google Patents

MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY.

Info

Publication number
UY27662A1
UY27662A1 UY27662A UY27662A UY27662A1 UY 27662 A1 UY27662 A1 UY 27662A1 UY 27662 A UY27662 A UY 27662A UY 27662 A UY27662 A UY 27662A UY 27662 A1 UY27662 A1 UY 27662A1
Authority
UY
Uruguay
Prior art keywords
inhibitors
mocrogly
interleucine
ifny
interrupt
Prior art date
Application number
UY27662A
Other languages
Spanish (es)
Inventor
Thorsten Blume
Wolfgang Halfbrodt
Joachin Kuhnke
Ursula Monning
Bernd Elger
Herbert Schneider
Wolf-Dietrich Docke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27662A1 publication Critical patent/UY27662A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de inhibidores de la microglía para preparar fármacos que inhiben las reacciones inmunes asociadas con monocitos, macrófagos y células-T y su uso para el tratamiento de enfermedades inmunológicas asociadas con células-T y reacciones inflamatorias no asociadas con células -T.Use of microglia inhibitors to prepare drugs that inhibit immune reactions associated with monocytes, macrophages and T-cells and their use for the treatment of immunological diseases associated with T-cells and inflammatory reactions not associated with -T cells.

UY27662A 2002-02-15 2003-02-11 MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY. UY27662A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (en) 2002-02-15 2002-02-15 Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses

Publications (1)

Publication Number Publication Date
UY27662A1 true UY27662A1 (en) 2003-09-30

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27662A UY27662A1 (en) 2002-02-15 2003-02-11 MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY.

Country Status (21)

Country Link
EP (1) EP1474138A1 (en)
JP (1) JP2005522447A (en)
KR (1) KR20040084909A (en)
CN (1) CN1756546A (en)
AR (1) AR039556A1 (en)
AU (1) AU2003245523A1 (en)
BR (1) BR0307706A (en)
CA (1) CA2475770A1 (en)
DE (1) DE10207843A1 (en)
EC (1) ECSP045297A (en)
MX (1) MXPA04007943A (en)
NO (1) NO20043840L (en)
PE (1) PE20030906A1 (en)
PL (1) PL371327A1 (en)
RS (1) RS71304A (en)
RU (1) RU2004127677A (en)
TW (1) TW200306823A (en)
UA (1) UA81111C2 (en)
UY (1) UY27662A1 (en)
WO (1) WO2003068225A1 (en)
ZA (1) ZA200407382B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (en) * 2002-02-15 2003-09-04 Schering Ag 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives
WO2006097547A1 (en) * 2005-03-17 2006-09-21 Proyecto De Biomedicina Cima S.L. Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
BR112014030940B1 (en) * 2012-06-11 2022-09-06 UCB Biopharma SRL BENZIMIDAZOLS THAT MODULATE TNF-ALFA AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
PL3371190T3 (en) 2015-11-06 2022-11-07 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
PL3390367T3 (en) * 2015-12-15 2021-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
AR107293A1 (en) 2016-01-05 2018-04-18 Incyte Corp PIRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-g INHIBITORS
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JP7244504B2 (en) 2017-10-18 2023-03-22 インサイト・コーポレイション Fused Imidazole Derivatives Substituted with Tertiary Hydroxy Groups as PI3K-γ Inhibitors
CR20210165A (en) 2018-09-05 2021-10-01 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
FI3860998T3 (en) 2018-10-05 2024-03-27 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity
CN112341451B (en) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 Immunomodulator
CN112341450B (en) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 Immunomodulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (en) * 1993-09-09 1995-03-16 Schering Ag New benzimidazole derivatives, processes for their preparation and their pharmaceutical use
MXPA02005742A (en) * 2000-01-14 2002-09-18 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation.
DE10134775A1 (en) * 2001-07-06 2003-01-30 Schering Ag 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives
DE10135050A1 (en) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
AR039556A1 (en) 2005-02-23
NO20043840L (en) 2004-11-12
DE10207843A1 (en) 2003-09-04
ZA200407382B (en) 2005-09-14
EP1474138A1 (en) 2004-11-10
CN1756546A (en) 2006-04-05
KR20040084909A (en) 2004-10-06
JP2005522447A (en) 2005-07-28
ECSP045297A (en) 2004-10-26
CA2475770A1 (en) 2003-08-21
MXPA04007943A (en) 2004-11-26
WO2003068225A1 (en) 2003-08-21
TW200306823A (en) 2003-12-01
BR0307706A (en) 2005-01-11
RU2004127677A (en) 2005-06-10
UA81111C2 (en) 2007-12-10
PE20030906A1 (en) 2004-01-17
PL371327A1 (en) 2005-06-13
RS71304A (en) 2006-10-27
AU2003245523A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
UY27662A1 (en) MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY.
CR7875A (en) IMMUNOGLOBIN VARIANTS AND USES OF THIS
ES2148525T3 (en) IMMUNOMODULATORS.
DE60332358D1 (en) PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
UY34901A (en) ? CRYSTALLINE MONOHIDRATE, PROCEDURE FOR ITS PREPARATION AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT ?.
ATE181227T1 (en) STRETCHY ABSORBENT STRUCTURE
MX9400166A (en) VEGETABLE PROTEIN MICROSPHERES, HYDROLYZED, MODIFIED AND METHODS FOR THEIR PREPARATION AND USE.
AR095541A1 (en) INTERLEUCINE-2 MUTEINS (IL-2) FOR THE EXPANSION OF REGULATORY T-CELLS
UY27720A1 (en) MONOCYCLIC AROILPIRIDINONES,
AR027221A1 (en) CORTICOTROPINE RELEASE FACTOR ANTAGONISTS
BRPI0417072B8 (en) "use of an interleukin-6(il-6) antagonist".
AR040130A1 (en) ETONOGESTREL ESTERES, ITS USE AS ANTICOPCEPTIVE AND FOR THE TREATMENT OF GYNECOLOGICAL DISORDERS
UY27725A1 (en) CRYSTALLINE MICRONIZED MATERIAL, PROCEDURE FOR ITS PREPARATION AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT.
UY26370A1 (en) "IMIDAZO-5-IL-AMICAS BICÍCLICAS, DRUGS CONTAINING THEM, THEIR USE FOR THE PREPARATION OF DRUGS AND PROCEDURE FOR THE PREPARATION".
CL2003002678A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, RECRUITOR ACTIVITY MODULATORS CCR5; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION, AND ITS USE IN THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY DISEASES, ASTHMA, Rheumatoid Arthritis and Atheroscle
UY28080A1 (en) POSITIONAL ISOMERS OF IFN PEG ALFA 2A
PT1492773E (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
CR7441A (en) MICROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY
IT1299264B1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF SKIN DISEASES ON AN INFLAMMATORY, IMMUNE OR PROLIFERATIVE BASIS
UY27312A1 (en) NEW HETEROCICLOS 3
AR027694A1 (en) USE OF MY PROTEIN FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ES2145114T3 (en) COMBINATION OF ATOVACUONA WITH PROGUANIL FOR THE TREATMENT OF PROTOZOARY INFECTIONS.
ES2118248T3 (en) 9-CHLORINE-PROSTAGLANDINE ESTERS AND AMIDES AND THEIR USE TO PREPARE MEDICINES.
ATE431742T1 (en) MODIFIED CYTOKINE FOR CANCER THERAPY
CR7442A (en) DERIVATIVES OF BENZIMIDAZOL 1-FENIL-2- HETEROARIL- SUBSTITUTED, ITS USE TO PREPARE MEDICATIONS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150428